Comparative Performances of LIVERFASt, Fibroscan and other NITs for severe fibrosis in NAFLD patients (Bordeaux cohort) easlfibronostg on June 26, 2026 Category: Publications Tag: Diabetes, Identification, LIVERFASt, MASLD, NAFLD Post navigation Previous: Previous post: Simulating clinical confidence intervals for black-box algorithmic predictions of liver steatosisNext: Next post: Predictive Value of LIVERFASt, ARFI-FIB-4 to identify chronic Hepatitis B (CHB) — NUH Singapore cohort